Global PD-1 and PD-L1 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global PD-1 and PD-L1 Inhibitor market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of PD-1 and PD-L1 Inhibitor include Bristol Myers Squibb, Bristol-Myers Squibb, Regeneron Pharmaceuticals, AstraZeneca, Beigene, Hengrui Medicine, Pfizer, Junshi Biosciences and Akeso, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for PD-1 and PD-L1 Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of PD-1 and PD-L1 Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for PD-1 and PD-L1 Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the PD-1 and PD-L1 Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global PD-1 and PD-L1 Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for PD-1 and PD-L1 Inhibitor sales, projected growth trends, production technology, application and end-user industry.
PD-1 and PD-L1 Inhibitor Segment by Company
Bristol Myers Squibb
Bristol-Myers Squibb
Regeneron Pharmaceuticals
AstraZeneca
Beigene
Hengrui Medicine
Pfizer
Junshi Biosciences
Akeso
Alphamab Oncology
Roche
Merck
Sanofi
Innovent Biologics
PD-1 and PD-L1 Inhibitor Segment by Type
Monoclonal Antibody
Bispecific Antibody
PD-1 and PD-L1 Inhibitor Segment by Application
Lung Cancer
Breast Cancer
Stomach Cancer
Rectal Cancer
Others
PD-1 and PD-L1 Inhibitor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1 and PD-L1 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PD-1 and PD-L1 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1 and PD-L1 Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the PD-1 and PD-L1 Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PD-1 and PD-L1 Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of PD-1 and PD-L1 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of PD-1 and PD-L1 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
According to APO Research, The global PD-1 and PD-L1 Inhibitor market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of PD-1 and PD-L1 Inhibitor include Bristol Myers Squibb, Bristol-Myers Squibb, Regeneron Pharmaceuticals, AstraZeneca, Beigene, Hengrui Medicine, Pfizer, Junshi Biosciences and Akeso, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for PD-1 and PD-L1 Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of PD-1 and PD-L1 Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for PD-1 and PD-L1 Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the PD-1 and PD-L1 Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global PD-1 and PD-L1 Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for PD-1 and PD-L1 Inhibitor sales, projected growth trends, production technology, application and end-user industry.
PD-1 and PD-L1 Inhibitor Segment by Company
Bristol Myers Squibb
Bristol-Myers Squibb
Regeneron Pharmaceuticals
AstraZeneca
Beigene
Hengrui Medicine
Pfizer
Junshi Biosciences
Akeso
Alphamab Oncology
Roche
Merck
Sanofi
Innovent Biologics
PD-1 and PD-L1 Inhibitor Segment by Type
Monoclonal Antibody
Bispecific Antibody
PD-1 and PD-L1 Inhibitor Segment by Application
Lung Cancer
Breast Cancer
Stomach Cancer
Rectal Cancer
Others
PD-1 and PD-L1 Inhibitor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1 and PD-L1 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PD-1 and PD-L1 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1 and PD-L1 Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the PD-1 and PD-L1 Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PD-1 and PD-L1 Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of PD-1 and PD-L1 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of PD-1 and PD-L1 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Table of Contents
199 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global PD-1 and PD-L1 Inhibitor Market Size, 2020 VS 2024 VS 2031
- 1.3 Global PD-1 and PD-L1 Inhibitor Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global PD-1 and PD-L1 Inhibitor Sales Estimates and Forecasts (2020-2031)
- 1.5 Global PD-1 and PD-L1 Inhibitor Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global PD-1 and PD-L1 Inhibitor Market Dynamics
- 2.1 PD-1 and PD-L1 Inhibitor Industry Trends
- 2.2 PD-1 and PD-L1 Inhibitor Industry Drivers
- 2.3 PD-1 and PD-L1 Inhibitor Industry Opportunities and Challenges
- 2.4 PD-1 and PD-L1 Inhibitor Industry Restraints
- 3 PD-1 and PD-L1 Inhibitor Market by Manufacturers
- 3.1 Global PD-1 and PD-L1 Inhibitor Revenue by Manufacturers (2020-2025)
- 3.2 Global PD-1 and PD-L1 Inhibitor Sales by Manufacturers (2020-2025)
- 3.3 Global PD-1 and PD-L1 Inhibitor Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global PD-1 and PD-L1 Inhibitor Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global PD-1 and PD-L1 Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global PD-1 and PD-L1 Inhibitor Manufacturers, Product Type & Application
- 3.7 Global PD-1 and PD-L1 Inhibitor Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global PD-1 and PD-L1 Inhibitor Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 PD-1 and PD-L1 Inhibitor Players Market Share by Revenue in 2024
- 3.8.3 2024 PD-1 and PD-L1 Inhibitor Tier 1, Tier 2, and Tier 3
- 4 PD-1 and PD-L1 Inhibitor Market by Type
- 4.1 PD-1 and PD-L1 Inhibitor Type Introduction
- 4.1.1 Monoclonal Antibody
- 4.1.2 Bispecific Antibody
- 4.2 Global PD-1 and PD-L1 Inhibitor Sales by Type
- 4.2.1 Global PD-1 and PD-L1 Inhibitor Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global PD-1 and PD-L1 Inhibitor Sales by Type (2020-2031)
- 4.2.3 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2020-2031)
- 4.3 Global PD-1 and PD-L1 Inhibitor Revenue by Type
- 4.3.1 Global PD-1 and PD-L1 Inhibitor Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global PD-1 and PD-L1 Inhibitor Revenue by Type (2020-2031)
- 4.3.3 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2020-2031)
- 5 PD-1 and PD-L1 Inhibitor Market by Application
- 5.1 PD-1 and PD-L1 Inhibitor Application Introduction
- 5.1.1 Lung Cancer
- 5.1.2 Breast Cancer
- 5.1.3 Stomach Cancer
- 5.1.4 Rectal Cancer
- 5.1.5 Others
- 5.2 Global PD-1 and PD-L1 Inhibitor Sales by Application
- 5.2.1 Global PD-1 and PD-L1 Inhibitor Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global PD-1 and PD-L1 Inhibitor Sales by Application (2020-2031)
- 5.2.3 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2020-2031)
- 5.3 Global PD-1 and PD-L1 Inhibitor Revenue by Application
- 5.3.1 Global PD-1 and PD-L1 Inhibitor Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global PD-1 and PD-L1 Inhibitor Revenue by Application (2020-2031)
- 5.3.3 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2020-2031)
- 6 Global PD-1 and PD-L1 Inhibitor Sales by Region
- 6.1 Global PD-1 and PD-L1 Inhibitor Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global PD-1 and PD-L1 Inhibitor Sales by Region (2020-2031)
- 6.2.1 Global PD-1 and PD-L1 Inhibitor Sales by Region (2020-2025)
- 6.2.2 Global PD-1 and PD-L1 Inhibitor Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America PD-1 and PD-L1 Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America PD-1 and PD-L1 Inhibitor Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe PD-1 and PD-L1 Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe PD-1 and PD-L1 Inhibitor Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific PD-1 and PD-L1 Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global PD-1 and PD-L1 Inhibitor Revenue by Region
- 7.1 Global PD-1 and PD-L1 Inhibitor Revenue by Region
- 7.1.1 Global PD-1 and PD-L1 Inhibitor Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global PD-1 and PD-L1 Inhibitor Revenue by Region (2020-2025)
- 7.1.3 Global PD-1 and PD-L1 Inhibitor Revenue by Region (2026-2031)
- 7.1.4 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America PD-1 and PD-L1 Inhibitor Revenue (2020-2031)
- 7.2.2 North America PD-1 and PD-L1 Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe PD-1 and PD-L1 Inhibitor Revenue (2020-2031)
- 7.3.2 Europe PD-1 and PD-L1 Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific PD-1 and PD-L1 Inhibitor Revenue (2020-2031)
- 7.4.2 Asia-Pacific PD-1 and PD-L1 Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Bristol Myers Squibb
- 8.1.1 Bristol Myers Squibb Comapny Information
- 8.1.2 Bristol Myers Squibb Business Overview
- 8.1.3 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
- 8.1.5 Bristol Myers Squibb Recent Developments
- 8.2 Bristol-Myers Squibb
- 8.2.1 Bristol-Myers Squibb Comapny Information
- 8.2.2 Bristol-Myers Squibb Business Overview
- 8.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
- 8.2.5 Bristol-Myers Squibb Recent Developments
- 8.3 Regeneron Pharmaceuticals
- 8.3.1 Regeneron Pharmaceuticals Comapny Information
- 8.3.2 Regeneron Pharmaceuticals Business Overview
- 8.3.3 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Portfolio
- 8.3.5 Regeneron Pharmaceuticals Recent Developments
- 8.4 AstraZeneca
- 8.4.1 AstraZeneca Comapny Information
- 8.4.2 AstraZeneca Business Overview
- 8.4.3 AstraZeneca PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 AstraZeneca PD-1 and PD-L1 Inhibitor Product Portfolio
- 8.4.5 AstraZeneca Recent Developments
- 8.5 Beigene
- 8.5.1 Beigene Comapny Information
- 8.5.2 Beigene Business Overview
- 8.5.3 Beigene PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Beigene PD-1 and PD-L1 Inhibitor Product Portfolio
- 8.5.5 Beigene Recent Developments
- 8.6 Hengrui Medicine
- 8.6.1 Hengrui Medicine Comapny Information
- 8.6.2 Hengrui Medicine Business Overview
- 8.6.3 Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Portfolio
- 8.6.5 Hengrui Medicine Recent Developments
- 8.7 Pfizer
- 8.7.1 Pfizer Comapny Information
- 8.7.2 Pfizer Business Overview
- 8.7.3 Pfizer PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 Pfizer PD-1 and PD-L1 Inhibitor Product Portfolio
- 8.7.5 Pfizer Recent Developments
- 8.8 Junshi Biosciences
- 8.8.1 Junshi Biosciences Comapny Information
- 8.8.2 Junshi Biosciences Business Overview
- 8.8.3 Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.8.4 Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Portfolio
- 8.8.5 Junshi Biosciences Recent Developments
- 8.9 Akeso
- 8.9.1 Akeso Comapny Information
- 8.9.2 Akeso Business Overview
- 8.9.3 Akeso PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.9.4 Akeso PD-1 and PD-L1 Inhibitor Product Portfolio
- 8.9.5 Akeso Recent Developments
- 8.10 Alphamab Oncology
- 8.10.1 Alphamab Oncology Comapny Information
- 8.10.2 Alphamab Oncology Business Overview
- 8.10.3 Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.10.4 Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Portfolio
- 8.10.5 Alphamab Oncology Recent Developments
- 8.11 Roche
- 8.11.1 Roche Comapny Information
- 8.11.2 Roche Business Overview
- 8.11.3 Roche PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.11.4 Roche PD-1 and PD-L1 Inhibitor Product Portfolio
- 8.11.5 Roche Recent Developments
- 8.12 Merck
- 8.12.1 Merck Comapny Information
- 8.12.2 Merck Business Overview
- 8.12.3 Merck PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.12.4 Merck PD-1 and PD-L1 Inhibitor Product Portfolio
- 8.12.5 Merck Recent Developments
- 8.13 Sanofi
- 8.13.1 Sanofi Comapny Information
- 8.13.2 Sanofi Business Overview
- 8.13.3 Sanofi PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.13.4 Sanofi PD-1 and PD-L1 Inhibitor Product Portfolio
- 8.13.5 Sanofi Recent Developments
- 8.14 Innovent Biologics
- 8.14.1 Innovent Biologics Comapny Information
- 8.14.2 Innovent Biologics Business Overview
- 8.14.3 Innovent Biologics PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.14.4 Innovent Biologics PD-1 and PD-L1 Inhibitor Product Portfolio
- 8.14.5 Innovent Biologics Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 PD-1 and PD-L1 Inhibitor Value Chain Analysis
- 9.1.1 PD-1 and PD-L1 Inhibitor Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 PD-1 and PD-L1 Inhibitor Production Mode & Process
- 9.2 PD-1 and PD-L1 Inhibitor Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 PD-1 and PD-L1 Inhibitor Distributors
- 9.2.3 PD-1 and PD-L1 Inhibitor Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
